Barclays
CATX icon

Barclays’s Perspective Therapeutics CATX Stock Holding History

Barclays’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.8K Sell
15,049
-77,742
-84% -$328K ﹤0.01% 4227
2025
Q4 		$255K Buy
92,791
+8,936
+11% +$25.5K ﹤0.01% 4197
2025
Q3 		$288K Sell
83,855
-19,426
-19% -$70.8K ﹤0.01% 4130
2025
Q2 		$355K Buy
103,281
+45,388
+78% +$120K ﹤0.01% 3949
2025
Q1 		$123K Sell
57,893
-36,986
-39% -$111K ﹤0.01% 4316
2024
Q4 		$303K Sell
94,879
-19,196
-17% -$157K ﹤0.01% 4116
2024
Q3 		$1.52M Buy
114,075
+97,493
+588% +$1.3M ﹤0.01% 3072
2024
Q2 		$165K Buy
16,582
+9,681
+140% +$140K ﹤0.01% 3675
2024
Q1 		$82.1K Buy
+6,901
New +$58.8K ﹤0.01% 4502
2021
Q2 		– Sell
-174
Closed -$2K – 4882
2021
Q1 		$2K Buy
+174
New +$2.63K ﹤0.01% 4552
2018
Q2 		– Hold
0
– – – 6986
2018
Q1 		– Hold
0
– – – 7070

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's CATX Position: Q1 2026 in Review

Barclays reduced its Perspective Therapeutics (CATX) stake by 84% in Q1 2026, selling an estimated $328K and leaving 15,049 shares worth $62.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

Barclays first reported a position in CATX in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.52M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Barclays held 15,049 shares of Perspective Therapeutics worth $62.8K as of Q1 2026.
  • Barclays sold 77,742 Perspective Therapeutics shares in Q1 2026, an estimated $328K.
  • Perspective Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4227 holding.
  • Barclays first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Barclays's Perspective Therapeutics position peaked at $1.52M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.